Aurobindo Pharma Ltd has received US Food and Drug Administration (USFDA) approval to manufacture and market generic versions of epilepsy drug levetiracetam in variable strengths.

Aurobindo will manufacture and market the tablet in dosages of 250 milligram, 500 mg, 750 mg and 1,000 mg and an oral solution in 100 mg per millilitre dose.

Levetiracetam is an anticonvulsant drug used for the treatment of epilepsy. It is S- enantiomer of etiracetam, structurally similar to the prototypical nootropic drug piracetam.

Total annual market for these drugs, the generic equivalent of UCB Inc.'s Keppra pills and Keppra oral solution, were $1.15 billion.

At 2:05 p.m., shares of Aurbindo Pharma gained 0.32% to trade at Rs 143.10 at the Bombay Stock Exchange (BSE).